Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Atossa Genetics Inc (NQ: ATOS )

2.910 USD +0.130 (+4.68%)
Official Closing Price Updated: 4:54 PM EST, Feb 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Atossa Genetics Inc

< Previous 1 2 3 4 Next >
Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19
From GlobeNewswire News Releases
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Accomplishments and Strategy for 2021
From GlobeNewswire News Releases
Thinking about buying stock in Zomedica, Nokia, Zynerba Pharmaceuticals, Senseonics Holdings, or Atossa Therapeutics?
InvestorsObserver issues critical PriceWatch Alerts for ZOM, NOK, ZYNE, SENS, and ATOS. 
From PR Newswire
Thinking about buying stock in Anavex Life Sciences, Lizhi, vTv Therapeutics, Atossa Therapeutics, or Cyclo Therapeutics?
InvestorsObserver issues critical PriceWatch Alerts for AVXL, LIZI, VTVT, ATOS, and CYTH. 
From PR Newswire
Atossa Therapeutics Announces Two-Year Update of FDA-Approved Expanded Access Treatment with Endoxifen
From GlobeNewswire News Releases
Atossa Therapeutics’ Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study to be Halted Early
From GlobeNewswire News Releases
Atossa Therapeutics Receives $21 Million from Recent Exercises of Outstanding Warrants
From GlobeNewswire News Releases
New Study By Dr. Steven Quay Concludes that SARS-CoV-2 Came from a Laboratory
Wuhan Institute of Virology Research in December 2019 Shows Evidence of Adenovirus Vaccine Experiments in Patients with COVID-19 
From PR Newswire
Registration Is Now Open For Tribe Public’s Webinar Event “The Important Role of COVID Therapeutics in a Post-Vaccine World” Featuring Atossa Therapeutics’ CEO & CFO On February 2, 2021
Meet With Atossa’s CEO Dr. Steven Quay, M.D., Ph.D. & CFO Kyle Guse who will deliver a presentation titled “The Important Role of COVID Therapeutics in a Post Vaccine World” 
From GlobeNewswire News Releases
Thinking about buying stock in Phio Pharmaceuticals, Allena Pharmaceuticals, Aemetis, Atossa Therapeutics, or Heat Biologics?
InvestorsObserver issues critical PriceWatch Alerts for PHIO, ALNA, AMTX, ATOS, and HTBX. 
From PR Newswire
Thinking about buying stock in Acer Therapeutics, Zomedica, Novan, Atossa Therapeutics, or Tellurian?
InvestorsObserver issues critical PriceWatch Alerts for ACER, ZOM, NOVN, ATOS, and TELL. 
From PR Newswire
Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021
From GlobeNewswire News Releases
Thinking about buying stock in iBio, Fluidigm Corp, Atossa Therapeutics, BioCryst Pharmaceuticals, or GameStop?
InvestorsObserver issues critical PriceWatch Alerts for IBIO, FLDM, ATOS, BCRX, and GME. 
From PR Newswire
COVID-19 Origin and Spread Linked to PLA Hospital and Wuhan Metro System Line 2 by Physician-Scientist Dr. Steven Quay
Dr. Steven Quay, M.D., PhD., head of two COVID-19 therapeutic programs at Atossa Therapeutics, Inc. (NASDAQ: ATOS ), recently shared his latest research and findings regarding the origins of COVID-19... 
From PR Newswire
Atossa Therapeutics Announces Pricing of $25.2 Million Registered Direct Offering Priced At-The-Market
From GlobeNewswire News Releases
Atossa Therapeutics Announces Pricing of $14.0 Million Registered Direct Offering Priced At-The-Market
From GlobeNewswire News Releases
Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering
From GlobeNewswire News Releases
Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19
From GlobeNewswire News Releases
New Research Points to the People's Liberation Army Hospital in Wuhan, China as the Origin for the Worldwide Coronavirus Pandemic
A paper published on Zenodo (DOI 10.5281/zenodo.4119263) by Dr. Steven Quay, M.D., PhD., head of two COVID-19 therapeutic programs at Atossa Therapeutics, Inc. (NASDAQ: ATOS), illuminates new... 
From PR Newswire
Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID
From GlobeNewswire News Releases
Registration Is Now Open For Atossa Therapeutics’ Tribe Public Webinar Presentation and Q&A Event On October 13, 2020
In honor of October Breast Cancer Awareness Month, Atossa’s CEO Dr. Steven Quay, M.D., Ph.D. & CFO Kyle Guse will deliver a presentation titled “Atossa Therapeutics: Tackling our Greatest Health... 
From GlobeNewswire News Releases
Physician-Scientist Dr. Steven Quay Provides Best-Selling Book, "Stay Safe: A Physician's Guide to Survive Coronavirus," to the White House Upon the News of COVID in the First Family
According to Dr. Quay, MD, PhD, "the book provides lifesaving tips you can't find anywhere else to help you and your family stay safe" 
From PR Newswire
Atossa Therapeutics To Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on September 22, 2020
From GlobeNewswire News Releases
Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID
Safety Committee Allows Enrollment in First 14-Day, Multi-Dose Study Arm 
From GlobeNewswire News Releases
Physician-Scientist Dr. Steven Quay's "Stay Safe: A Physician's Guide to Survive Coronavirus" Reaches #1 on Five Amazon Bestsellers Lists
"The Guide Offers Simple Tips to Help Protect You and Your Family Against the Coronavirus" 
From PR Newswire
Physician-Scientist Dr. Steven Quay Shares Back-to-School Tips To Stay Safe and Survive Coronavirus
"Simple and Affordable Salt Spray Uses Everyday Household Ingredients to Help Protect You Against the Coronavirus" 
From PR Newswire
Atossa Therapeutics Announces Positive Interim Safety Assessment of First Group of Participants in Clinical Study of AT-301 Nasal Spray Being Developed for COVID-19
From GlobeNewswire News Releases
New COVID-19 Survival Manual Offers Tips from Renowned Physician Scientist to Keep You and Your Family Healthy During the Pandemic
"The Book Includes Prevention and Treatments Tips to Keep You Safe for Back-to-School, Cold & Flu Season, and Beyond" 
From PR Newswire
Atossa Therapeutics to Present at the LD Micro 500 Virtual Conference on September 4, 2020
From GlobeNewswire News Releases
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.